Hepatology Highlights

Muzammil Muhammad Khan, Maria Alejandra Luna‐Cuadros, Daryl T.Y. Lau, Tejasav S. Sehrawat, Ojasav Sehrawat, Robert E. Schwartz, Anthony J. Choi, Robert S. Brown, Gopanandan Parthasarathy, Enis Kostallari, Nidhi Jalan‐Sakrikar, David M. Salerno, Chaitanya Allamneni, Ravi S. Vora, Jessica L. Maiers – 17 June 2021

Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B

Florian Bömmel, Thomas Berg – 17 June 2021 – Systematic discontinuation of long‐term treatment with nucleos(t)ide analogues (NAs) is one strategy to increase functional cure rates in patients with chronic hepatitis B e antigen (HBeAg)–negative hepatitis B. Currently, available study results are heterogeneous; however, long‐term hepatitis B surface antigen (HBsAg) loss rates of up to 20% have been reported in prospective trials. This review proposes criteria that can be used when considering NA discontinuation in patients with chronic hepatitis B virus (HBV).

Estimating Glomerular Filtration Rate in Cirrhosis Using Creatinine‐Based and Cystatin C–Based Equations: Systematic Review and Meta‐Analysis

Prianka Singapura, Tsung‐Wei Ma, Naveed Sarmast, Stevan A. Gonzalez, François Durand, Rakhi Maiwall, Mitra K. Nadim, John Fullinwider, Giovanna Saracino, Claire Francoz, Rebecca Sartin, James F. Trotter, Sumeet K. Asrani – 17 June 2021 – Accurate estimation of kidney function in cirrhosis is crucial for prognosis and decisions regarding dual‐organ transplantation. We performed a systematic review/meta‐analysis to assess the performance of creatinine‐based and cystatin C (CysC)–based eGFR equations compared with measured GFR (mGFR) in patients with cirrhosis.

Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD

Hirokazu Takahashi, Takaomi Kessoku, Miwa Kawanaka, Michihiro Nonaka, Hideyuki Hyogo, Hideki Fujii, Tomoaki Nakajima, Kento Imajo, Kenichi Tanaka, Yoshihito Kubotsu, Hiroshi Isoda, Satoshi Oeda, Osamu Kurai, Masato Yoneda, Masafumi Ono, Yoichiro Kitajima, Ryo Tajiri, Ayako Takamori, Atsushi Kawaguchi, Shinichi Aishima, Masayoshi Kage, Atsushi Nakajima, Yuichiro Eguchi, Keizo Anzai – 16 June 2021 – Sodium glucose cotransporter‐2 inhibitors (SGLT2is) are now widely used to treat diabetes, but their effects on nonalcoholic fatty liver disease (NAFLD) remain to be determined.

LiverLearning®: 2021 Webinar: NASH as a Cause of Hepatocellular Carcinoma

Learn about epidemiology of NASH-HCC, differences in NASH-HCC compared to other etiologies and prevention and management of NASH-HCC. Presenters will discuss the rising burden of NASH-HCC such as its contribution to liver transplant, morbidity and mortality and cost. Along with differences in gender, presentation, prognosis and screening data, prevention, treatments such as resection versus liver transplant versus other therapies.Zobair M. Younossi Zobair M.

TNFAIP3 Interacting Protein 3 Is an Activator of Hippo‐YAP Signaling Protecting Against Hepatic Ischemia/Reperfusion Injury

Junjie Zhou, Manli Hu, Meiling He, Xiaoming Wang, Dating Sun, Yongping Huang, Xu Cheng, Jiajun Fu, Jie Cai, Tengfei Ma, Song Tian, Yufeng Hu, Fengjiao Hu, Dan Liu, Yanqi He, Lanlan Yan, Zhi‐Gang She, Xiao‐Jing Zhang, Yan‐Xiao Ji, Hui Liu, Hongliang Li, Hailong Yang, Peng Zhang – 15 June 2021

Subscribe to